pancreata  (Worthington Biochemical)


Bioz Verified Symbol Worthington Biochemical is a verified supplier
Bioz Manufacturer Symbol Worthington Biochemical manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Name:
    Collagenase Type 4
    Description:
    Prepared to contain lower tryptic activity levels to limit damage to membrane proteins and receptors but with normal to above normal collagenase activity Suggested for pancreatic islet primary isolation A dialyzed lyophilized powder
    Catalog Number:
    ls004186
    Price:
    35
    Size:
    100 mg
    Source:
    Clostridium histolyticum
    Cas Number:
    9001.12.1
    Buy from Supplier


    Structured Review

    Worthington Biochemical pancreata
    Inhibition of RIP1 signaling mitigates TAM infiltration and reprograms TAMs in PDA. (A-I) WT mice bearing orthotopic KPC tumors were treated with RIP1i or control and were sacrificed at 21 days (n=5/group). IHC of PDA tumors for F4/80 (scale bar = 100 μm) (A). The percentage of Gr1 − CD11c − F480 + CD11b + TAM was determined by flow cytometry (B) . TAMs were tested for expression of MHC-II, CD86 (C) , TNFα, CD80 (D) , IFNγ (E) , CD206 (F) , IL-10 (G) , and TGF-β (H) . <t>Pancreata</t> were analyzed for expression of Arg1 by IHC (scale bar = 100 μm) (I) . (J) WT and RIP1 KD/KI mice bearing orthotopic KPC tumors were sacrificed at 21 days and tumors were analyzed by flow cytometry. TAMs were tested for expression of MHC-II, CD206, TNFα, and CD86 (n=10/group). (K) Expression of MHC-II, TNFα, CD206, and IL-10 in TAMs isolated at day 21 from WT mice injected with KPC-derived tumor cells via portal venous and treated with RIP1i or control beginning on the day of tumor administration (n=5/group). Macrophage phenotyping experiments were repeated more than 5 times (*p
    Prepared to contain lower tryptic activity levels to limit damage to membrane proteins and receptors but with normal to above normal collagenase activity Suggested for pancreatic islet primary isolation A dialyzed lyophilized powder
    https://www.bioz.com/result/pancreata/product/Worthington Biochemical
    Average 92 stars, based on 1986 article reviews
    Price from $9.99 to $1999.99
    pancreata - by Bioz Stars, 2020-05
    92/100 stars

    Images

    1) Product Images from "RIP1 Kinase Drives Macrophage Mediated Adaptive Immune Tolerance in Pancreatic Cancer"

    Article Title: RIP1 Kinase Drives Macrophage Mediated Adaptive Immune Tolerance in Pancreatic Cancer

    Journal: Cancer cell

    doi: 10.1016/j.ccell.2018.10.006

    Inhibition of RIP1 signaling mitigates TAM infiltration and reprograms TAMs in PDA. (A-I) WT mice bearing orthotopic KPC tumors were treated with RIP1i or control and were sacrificed at 21 days (n=5/group). IHC of PDA tumors for F4/80 (scale bar = 100 μm) (A). The percentage of Gr1 − CD11c − F480 + CD11b + TAM was determined by flow cytometry (B) . TAMs were tested for expression of MHC-II, CD86 (C) , TNFα, CD80 (D) , IFNγ (E) , CD206 (F) , IL-10 (G) , and TGF-β (H) . Pancreata were analyzed for expression of Arg1 by IHC (scale bar = 100 μm) (I) . (J) WT and RIP1 KD/KI mice bearing orthotopic KPC tumors were sacrificed at 21 days and tumors were analyzed by flow cytometry. TAMs were tested for expression of MHC-II, CD206, TNFα, and CD86 (n=10/group). (K) Expression of MHC-II, TNFα, CD206, and IL-10 in TAMs isolated at day 21 from WT mice injected with KPC-derived tumor cells via portal venous and treated with RIP1i or control beginning on the day of tumor administration (n=5/group). Macrophage phenotyping experiments were repeated more than 5 times (*p
    Figure Legend Snippet: Inhibition of RIP1 signaling mitigates TAM infiltration and reprograms TAMs in PDA. (A-I) WT mice bearing orthotopic KPC tumors were treated with RIP1i or control and were sacrificed at 21 days (n=5/group). IHC of PDA tumors for F4/80 (scale bar = 100 μm) (A). The percentage of Gr1 − CD11c − F480 + CD11b + TAM was determined by flow cytometry (B) . TAMs were tested for expression of MHC-II, CD86 (C) , TNFα, CD80 (D) , IFNγ (E) , CD206 (F) , IL-10 (G) , and TGF-β (H) . Pancreata were analyzed for expression of Arg1 by IHC (scale bar = 100 μm) (I) . (J) WT and RIP1 KD/KI mice bearing orthotopic KPC tumors were sacrificed at 21 days and tumors were analyzed by flow cytometry. TAMs were tested for expression of MHC-II, CD206, TNFα, and CD86 (n=10/group). (K) Expression of MHC-II, TNFα, CD206, and IL-10 in TAMs isolated at day 21 from WT mice injected with KPC-derived tumor cells via portal venous and treated with RIP1i or control beginning on the day of tumor administration (n=5/group). Macrophage phenotyping experiments were repeated more than 5 times (*p

    Techniques Used: Inhibition, Mouse Assay, Immunohistochemistry, Flow Cytometry, Cytometry, Expressing, Isolation, Injection, Derivative Assay

    2) Product Images from "Innate αβ T cells Mediate Anti-tumor Immunity by Orchestrating Immunogenic Macrophage Programming"

    Article Title: Innate αβ T cells Mediate Anti-tumor Immunity by Orchestrating Immunogenic Macrophage Programming

    Journal: Cancer discovery

    doi: 10.1158/2159-8290.CD-19-0161

    iαβTs expand in PDA. (a) CD45 + leukocytes infiltrating day 21 orthotopic KPC tumors, normal pancreas, and spleens in WT mice were gated and tested for the frequency of TCRβ + CD4 – CD8 – NK1.1 – iαβTs. Representative contour plots and quantitative data are shown (n=10). (b) CD45 + TCRβ + NK1.1 – leukocytes from pancreata and spleens of 6 month-old KC mice were gated and tested for co-expression CD4 and CD8. Representative contour plots are shown (n=5). (c) Multiplex IHC of human PDA and adjacent normal pancreas were stained for CK19, CD3, CD4, and CD8. The frequency of CD3 + CD4 – CD8 – cells were quantified and representative images are shown. (d) Orthotopic KPC tumors were harvested from WT mice on day 21. CD45 + CD3 + leukocytes were purified by FACS and analyzed by single cell RNAseq. The distribution of cellular clusters was determined using the t-Distributed Stochastic Neighbor Embedding (t-SNE) algorithm. Each cluster is identified by a distinct color. Percent cellular abundance in each cluster is indicated. (e) Orthotopic KPC tumors were harvested from WT mice on days 7, 14, or 21 after tumor cell implantation and tumor-infiltrating CD45 + TCRβ + CD4 – CD8 – leukocytes were gated and tested for expression of NK1.1. Representative contour plots from days 7 and 21 and quantitative data comparing frequency of tumor-infiltrating iαβT per NKT cells at all time points are shown (n=5/time point). (f) Paraffin-embedded sections made from tumors of mice serially treated with anti-TCRγ/δ and NK1.1 depleting antibodies were tested for co-expression of Hematoxylin, CD3, CD4, and CD8 in the PDA TME. (g) CD45 + TCRβ + NK1.1 – leukocytes infiltrating orthotopic KPC tumors in WT and Fas lpr mice were gated and tested for expression of CD4 and CD8. Representative contour plots and quantitative data are shown (n=5/group). (h) The thymus from 6-month old WT and KC mice were harvested and CD45 + TCRβ + thymocytes were gated and tested for expression of CD4 and CD8. The frequency of iαβTs in the thymus was calculated (n=5/group). (i) CD4 + T cells, CD8 + T cells, or iαβTs were harvested from CD45.1 mice and transferred i.v. to orthotopic PDA-bearing CD45.2 mice. PDA tumors were harvested at 96 hours and CD45.1 + cells were gated and tested for CD4 and CD8 expression. Representative contour plots are shown (n=5/group). (j) WT mice were orthotopically administered KPC tumor cells and sacrificed on day 21. PDA-infiltrating CD4 + T cells, CD8 + T cells, and iαβTs were assayed for Ki67 proliferative index. Representative contour plots and quantitative data are shown (n=5). (k) Splenic and orthotopic PDA-infiltrating iαβTs were tested on day 21 for expression of CCR2, CCR5, and CCR6 (n=5). (l) The frequency of PDA-infiltrating iαβTs was tested on day 21 in WT, CCR2 –/– , CCR5 –/– , and CCR6 –/– hosts (n=5/group). All experiments were repeated at least 3 times (*p
    Figure Legend Snippet: iαβTs expand in PDA. (a) CD45 + leukocytes infiltrating day 21 orthotopic KPC tumors, normal pancreas, and spleens in WT mice were gated and tested for the frequency of TCRβ + CD4 – CD8 – NK1.1 – iαβTs. Representative contour plots and quantitative data are shown (n=10). (b) CD45 + TCRβ + NK1.1 – leukocytes from pancreata and spleens of 6 month-old KC mice were gated and tested for co-expression CD4 and CD8. Representative contour plots are shown (n=5). (c) Multiplex IHC of human PDA and adjacent normal pancreas were stained for CK19, CD3, CD4, and CD8. The frequency of CD3 + CD4 – CD8 – cells were quantified and representative images are shown. (d) Orthotopic KPC tumors were harvested from WT mice on day 21. CD45 + CD3 + leukocytes were purified by FACS and analyzed by single cell RNAseq. The distribution of cellular clusters was determined using the t-Distributed Stochastic Neighbor Embedding (t-SNE) algorithm. Each cluster is identified by a distinct color. Percent cellular abundance in each cluster is indicated. (e) Orthotopic KPC tumors were harvested from WT mice on days 7, 14, or 21 after tumor cell implantation and tumor-infiltrating CD45 + TCRβ + CD4 – CD8 – leukocytes were gated and tested for expression of NK1.1. Representative contour plots from days 7 and 21 and quantitative data comparing frequency of tumor-infiltrating iαβT per NKT cells at all time points are shown (n=5/time point). (f) Paraffin-embedded sections made from tumors of mice serially treated with anti-TCRγ/δ and NK1.1 depleting antibodies were tested for co-expression of Hematoxylin, CD3, CD4, and CD8 in the PDA TME. (g) CD45 + TCRβ + NK1.1 – leukocytes infiltrating orthotopic KPC tumors in WT and Fas lpr mice were gated and tested for expression of CD4 and CD8. Representative contour plots and quantitative data are shown (n=5/group). (h) The thymus from 6-month old WT and KC mice were harvested and CD45 + TCRβ + thymocytes were gated and tested for expression of CD4 and CD8. The frequency of iαβTs in the thymus was calculated (n=5/group). (i) CD4 + T cells, CD8 + T cells, or iαβTs were harvested from CD45.1 mice and transferred i.v. to orthotopic PDA-bearing CD45.2 mice. PDA tumors were harvested at 96 hours and CD45.1 + cells were gated and tested for CD4 and CD8 expression. Representative contour plots are shown (n=5/group). (j) WT mice were orthotopically administered KPC tumor cells and sacrificed on day 21. PDA-infiltrating CD4 + T cells, CD8 + T cells, and iαβTs were assayed for Ki67 proliferative index. Representative contour plots and quantitative data are shown (n=5). (k) Splenic and orthotopic PDA-infiltrating iαβTs were tested on day 21 for expression of CCR2, CCR5, and CCR6 (n=5). (l) The frequency of PDA-infiltrating iαβTs was tested on day 21 in WT, CCR2 –/– , CCR5 –/– , and CCR6 –/– hosts (n=5/group). All experiments were repeated at least 3 times (*p

    Techniques Used: Mouse Assay, Expressing, Multiplex Assay, Immunohistochemistry, Staining, Purification, FACS

    Related Articles

    Modification:

    Article Title: Induction of Expression of CD271 and CD34 in Mesenchymal Stromal Cells Cultured as Spheroids
    Article Snippet: .. Floating AT was removed, transferred to a 50 mL centrifuge tube containing an equal volume of collagenase solution (300 units of collagenase I (Worthington Biochemical Corp., Lakewood, NJ, USA)) per mL of Dulbecco's Modified Eagle's Medium-low bicarbonate containing 2% fetal bovine serum (DMEM-LB/2), and incubated at 37°C for 40 minutes in a water bath with intermittent swirling of the tubes. ..

    Concentration Assay:

    Article Title: Electrical Homogenization of Ventricular Scar by Application of Collagenase: A Novel Strategy for Arrhythmia Therapy
    Article Snippet: .. Three types of clostridial CLGs [Type 2 collagenase (CLG-2); Type 4 collagenase (CLG-4); and purified collagenase (CLSPA); Worthington Biochemical Corporation, NJ] were evaluated to identify the optimal CLG subtype, and concentration for scar homogenization. ..

    Incubation:

    Article Title: Induction of Expression of CD271 and CD34 in Mesenchymal Stromal Cells Cultured as Spheroids
    Article Snippet: .. Floating AT was removed, transferred to a 50 mL centrifuge tube containing an equal volume of collagenase solution (300 units of collagenase I (Worthington Biochemical Corp., Lakewood, NJ, USA)) per mL of Dulbecco's Modified Eagle's Medium-low bicarbonate containing 2% fetal bovine serum (DMEM-LB/2), and incubated at 37°C for 40 minutes in a water bath with intermittent swirling of the tubes. ..

    Purification:

    Article Title: Electrical Homogenization of Ventricular Scar by Application of Collagenase: A Novel Strategy for Arrhythmia Therapy
    Article Snippet: .. Three types of clostridial CLGs [Type 2 collagenase (CLG-2); Type 4 collagenase (CLG-4); and purified collagenase (CLSPA); Worthington Biochemical Corporation, NJ] were evaluated to identify the optimal CLG subtype, and concentration for scar homogenization. ..

    Homogenization:

    Article Title: Electrical Homogenization of Ventricular Scar by Application of Collagenase: A Novel Strategy for Arrhythmia Therapy
    Article Snippet: .. Three types of clostridial CLGs [Type 2 collagenase (CLG-2); Type 4 collagenase (CLG-4); and purified collagenase (CLSPA); Worthington Biochemical Corporation, NJ] were evaluated to identify the optimal CLG subtype, and concentration for scar homogenization. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Worthington Biochemical hyaluronidase hsep
    Hyaluronidase Hsep, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 95/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hyaluronidase hsep/product/Worthington Biochemical
    Average 95 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    hyaluronidase hsep - by Bioz Stars, 2020-05
    95/100 stars
      Buy from Supplier

    92
    Worthington Biochemical jensen js
    Jensen Js, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jensen js/product/Worthington Biochemical
    Average 92 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    jensen js - by Bioz Stars, 2020-05
    92/100 stars
      Buy from Supplier

    93
    Worthington Biochemical danielewski j
    Danielewski J, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/danielewski j/product/Worthington Biochemical
    Average 93 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    danielewski j - by Bioz Stars, 2020-05
    93/100 stars
      Buy from Supplier

    Image Search Results